Merck, Moderna link in personalised cancer vaccines deal
Merck and Moderna Therapeutics have linked under a strategic collaboration and license agreement to develop and commercialise cancer vaccines based on novel messenger RNA.
Read More
Tag: personalised vaccine
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
